JSR Corp. Wipes out Cytiva Antibody Tech Patents at Federal Cir.

JSR Corp. convinced a federal appeals court to wipe out all challenged claims in three Cytiva Bioprocess R&D AB patents concerning antibody technology.

The Patent and Trial Appeal Board was right to invalidate nearly 80 claims of US Patent Nos. 10,213,765, 10,343,142, and 10,875,007 as obvious, Judge Sharon Prost wrote for a three judge panel in a precedential opinion Wednesday in the US Court of Appeals for the Federal Circuit. The court affirmed the administrative tribunal’s invalidation of 79 claims across the patents, but reversed the board’s rulings upholding the validity of other challenged claims in the ‘142 ...